[Position paper on the use of drug eluting stents (DES) in percutaneous coronary interventions in patients with coronary heart disease]. - Suppr | 超能文献

[Position paper on the use of drug eluting stents (DES) in percutaneous coronary interventions in patients with coronary heart disease].

作者信息

Levenson B

机构信息

Kardiologische Gemeinschaftspraxis, Pestalozzistrasse 38, 10627 Berlin, Germany.

出版信息

Z Kardiol. 2003 Jul;92(7):606-12. doi: 10.1007/s00392-003-0970-z.

DOI:10.1007/s00392-003-0970-z

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

[Position paper on the use of drug eluting stents (DES) in percutaneous coronary interventions in patients with coronary heart disease].

Z Kardiol. 2003 Jul;92(7):606-12. doi: 10.1007/s00392-003-0970-z.

2

The paclitaxel-eluting stent in percutaneous coronary intervention: Part II. Comparison with the sirolimus-eluting stent, economics, and unanswered questions.

Cardiol Rev. 2006 May-Jun;14(3):143-50. doi: 10.1097/01.crd.0000214683.72810.87.

3

ABT-578-eluting stents. The promising successor of sirolimus- and paclitaxel-eluting stent concepts?

Herz. 2004 Mar;29(2):167-70. doi: 10.1007/s00059-004-2557-5.

4

Cost-effectiveness of the real-world use of drug-eluting stents at 9-month follow-up: results from the Sicilian DES Registry.

J Cardiovasc Med (Hagerstown). 2009 Apr;10(4):322-9. doi: 10.2459/JCM.0b013e3283276ebb.

5

Drug-eluting stents: the panacea for restenosis?

Singapore Med J. 2004 Jul;45(7):300-2.

6

Cost analysis from two randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in high-risk patients with coronary artery disease.

J Am Coll Cardiol. 2006 Jul 18;48(2):262-7. doi: 10.1016/j.jacc.2006.01.080. Epub 2006 Jun 22.

7

[Safety and current indications during "real life" use of sirolimus-eluting coronary stents in Germany. Results from the prospective multicenter German Cypher Registry].

Herz. 2004 Mar;29(2):181-6. doi: 10.1007/s00059-004-2560-x.

8

Classification and current treatment options of in-stent restenosis. Present status and future perspectives.

Herz. 2004 Mar;29(2):187-94. doi: 10.1007/s00059-004-2574-4.

9

Polymer-sirolimus-eluting stents in de novo lesions.

Herz. 2004 Mar;29(2):152-61. doi: 10.1007/s00059-004-2569-1.

10

Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents.

Herz. 2004 Mar;29(2):162-6. doi: 10.1007/s00059-004-2556-6.

引用本文的文献

1

Mechanism of Intermittent Deep Tillage and Different Depths Improving Crop Growth From the Perspective of Rhizosphere Soil Nutrients, Root System Architectures, Bacterial Communities, and Functional Profiles.

Front Microbiol. 2022 Jan 10;12:759374. doi: 10.3389/fmicb.2021.759374. eCollection 2021.

2

[Legal requirements for the coating of coronary stents with medications by cardiologists outside clinical investigations. Information of the Federal Institute for Medications and Medical Products and the central position of the various regions for health preservation in using medications and medical products (ZLG)].

Clin Res Cardiol. 2006 Jul;95(7):388-91. doi: 10.1007/s00392-006-0409-4. Epub 2006 Jun 2.